Christine Wilkinson-Blanc
Corporate Officer/Principal chez Centre Hospitalier Universitaire de Lille
Profil
Christine Wilkinson-Blanc is currently the Head-Clinic at Centre Hospitalier Universitaire de Lille.
She previously worked as a Medical Director at GE Healthcare Ltd.
(United Kingdom) and as a Chief Medical Officer at Akamis Bio Ltd.
and Nordic Nanovector ASA. She also worked as a Principal at Aventis International, Inc. Wilkinson-Blanc holds a doctorate degree from Université des Sciences et Technologies de Lille and the University of Lyon, and a graduate degree from Centre Hospitalier Universitaire de Lille.
Postes actifs de Christine Wilkinson-Blanc
| Sociétés | Poste | Début |
|---|---|---|
| Centre Hospitalier Universitaire de Lille | Corporate Officer/Principal | - |
Anciens postes connus de Christine Wilkinson-Blanc
| Sociétés | Poste | Fin |
|---|---|---|
| THOR MEDICAL | Directeur Technique/Scientifique/R&D | 08/11/2021 |
GE Healthcare Ltd. (United Kingdom)
 GE Healthcare Ltd. (United Kingdom) Medical SpecialtiesHealth Technology GE Healthcare Ltd. provides transformational medical technologies and services which include icenter, AssetPlus, preventive maintenance, continuity, digital solutions and Unisys multi brand probe repair services. The firm offers magnetic resonance imaging, hemodynamic recording, EP recording, metabolic health and computed tomography. The company was founded on February 16, 1971 and is headquartered in Little Chalfont, the United Kingdom. | Directeur Technique/Scientifique/R&D | - |
| Aventis International, Inc. | Corporate Officer/Principal | - |
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Directeur Technique/Scientifique/R&D | - |
Formation de Christine Wilkinson-Blanc
| University of Lyon | Doctorate Degree |
| Centre Hospitalier Universitaire de Lille | Graduate Degree |
| Université des Sciences et Technologies de Lille | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
GE Healthcare Ltd. (United Kingdom)
GE Healthcare Ltd. (United Kingdom) Medical SpecialtiesHealth Technology GE Healthcare Ltd. provides transformational medical technologies and services which include icenter, AssetPlus, preventive maintenance, continuity, digital solutions and Unisys multi brand probe repair services. The firm offers magnetic resonance imaging, hemodynamic recording, EP recording, metabolic health and computed tomography. The company was founded on February 16, 1971 and is headquartered in Little Chalfont, the United Kingdom. | Health Technology |
| Aventis International, Inc. | |
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
